Cannabidiol quinone derivatives

Abstract

The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

What is claimed is: 
     
       1. Compounds of Formula (I), or pharmaceutically acceptable salts thereof 
       
         
           
           
               
               
           
         
       
       wherein R is the carbon atom of a linear or branched group, represented by alkoxycarbonyl groups; or wherein R is the nitrogen atom of a linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. 
     
     
       2. Compound according to  claim 1  selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
       3. Compositions comprising a compound of  claim 1 , further comprising at least a pharmaceutical inert ingredient selected from an excipient or carrier. 
     
     
       4. Composition according to  claim 3  wherein the compound of formula (I) is selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
       5. A medicament comprising a compound of  claim 1 . 
     
     
       6. A method of treating a human or animal patient comprising administering an effective amount of a medicament comprising the compound of  claim 1  or a pharmaceutically acceptable salt thereof to the patient sufficient to ameliorate the symptoms of a disease, wherein the disease is a PPARg mediated disease. 
     
     
       7. The method of  claim 6 , wherein the PPARg mediated disease is selected from: atherosclerosis, inflammatory bowel diseases, rheumatoid arthritis, liver fibrosis, nephropathy, psoriasis, skin wound healing, skin regeneration, pancreatitis, gastritis, neurodegenerative disorders, neuroinflammatory disorders, scleroderma, cancer, hypertension, obesity, or type II diabetes.